<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5285">
  <stage>Registered</stage>
  <submitdate>14/10/2015</submitdate>
  <approvaldate>14/10/2015</approvaldate>
  <nctid>NCT02577029</nctid>
  <trial_identification>
    <studytitle>Study of ARC-520 With or Without Other Drugs Used in the Treatment of Chronic HBV</studytitle>
    <scientifictitle>A Multicenter, Open-Label Study to Evaluate ARC-520 Administered Alone and in Combination With Other Therapeutics in Patients With Chronic Hepatitis B Virus (HBV) Infection (MONARCH)</scientifictitle>
    <utrn />
    <trialacronym>Monarch</trialacronym>
    <secondaryid>Heparc-2008</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <healthcondition>Hepatitis D</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ARC-520
Treatment: drugs - Entecavir
Other interventions - Pegylated Interferon alpha 2a
Treatment: drugs - Tenofovir disoproxil

Experimental: ARC-520 administered alone - ARC-520 (2 mg/kg or 4 mg/kg every 4 weeks) for 48 weeks (13 doses).

Experimental: ARC-520 with nucleoside and Peginterferon - ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + entecavir (0.5 mg daily - about 60 weeks) or tenofovir (300 mg daily - about 60 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks

Experimental: ARC-520 with Peginterferon - ARC-520 (2 mg/kg every 4 weeks - 48 weeks) + Peginterferon alpha 2a (180 mcg weekly) - 48 weeks


Treatment: drugs: ARC-520


Treatment: drugs: Entecavir


Other interventions: Pegylated Interferon alpha 2a


Treatment: drugs: Tenofovir disoproxil


</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Percentage of patients achieving a 1-log reduction in Hepatitis B Surface Antigen (HBsAg) compared to baseline</outcome>
      <timepoint>Baseline to Week 60</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with HBsAg loss (based on qualitative assay) compared to baseline</outcome>
      <timepoint>Baseline and Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients achieving a 1-log reduction in HBsAg and achieving a HBsAg level &lt; 100 IU/L compared to baseline</outcome>
      <timepoint>Baseline and Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to HBsAg loss</outcome>
      <timepoint>Baseline through Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Time to anti-HBs (antibody to Hepatitis B Surface Antigen) seroconversion</outcome>
      <timepoint>Baseline through Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with anti-HBs seroconversion compared to baseline</outcome>
      <timepoint>Baseline and Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with Hepatitis B e Antigen (HBeAg) loss and Anti Hepatitis B e Antigen (Anti-HBe) seroconversion compared to baseline (if HBeAg positive at study entry)</outcome>
      <timepoint>Baseline and Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with resistance to ARC-520 compared from baseline to Week 52 - Resistance defined as &gt; 1.0 log IU/mL quantitative HBsAg (qHBsAg) increase from nadir, confirmed by repeat test.</outcome>
      <timepoint>Baseline and Week 52</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of patients with resistance to the combination therapy from baseline to Week 60 - Resistance defined as &gt; 1.0 log IU/mL increase in HBV DNA from nadir, confirmed by repeat test</outcome>
      <timepoint>Baseline and Week 60</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Incidence and frequency of adverse events as a measure of safety and tolerability of ARC-520 alone or when coadministered with combination therapy</outcome>
      <timepoint>Baseline to Week 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Percentage of HDV patients with undetectable HDV ribonucleic acid (RNA) after 48 weeks of concomitant ARC-520 and PEG IFN therapy</outcome>
      <timepoint>At Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Log change from baseline in quantitative HBV deoxyribonucleic acid (DNA)</outcome>
      <timepoint>Baseline and Weeks 52, 60, 72 and 96</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, 18 to 75 years of age

          -  Written informed consent

          -  No clinically significant abnormalities at screening/pre-dose 12-lead ECG assessment

          -  Diagnosis of HBeAg negative or positive chronic HBV infection.

          -  Must be HBsAg (+) during screening.

          -  Must be treatment na√Øve: Never on pegylated interferon alpha 2a (PEG INF) and/or
             entecavir (ETV) or tenofovir (TDF); and

          -  Have not used nucleoside/nucleotide analogs (NUCs) within the last 2 years prior to
             dosing on Day 1

          -  Must use 2 effective methods of contraception (double barrier contraception or
             hormonal contraceptive along with a barrier contraceptive) (both male and female
             partners)</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>75</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>No</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating

          -  Acute signs of hepatitis/other severe infections within 4 weeks of screening

          -  Use within the last 14 days or anticipated requirement for anticoagulants, systemic
             corticosteroids, immunomodulators, or immunosuppressants

          -  Use of prescription medication within 14 days prior to treatment administration
             except: topical products without systemic absorption, statins (except rosuvastatin),
             hypertension medications, over-the-counter (OTC) and prescription pain medication or
             hormonal contraceptives

          -  History of poorly controlled autoimmune disease or any history of autoimmune hepatitis

          -  History of heterozygous or homozygous familial hypercholesterolemia.

          -  Human immunodeficiency virus (HIV) infection

          -  Is sero-positive for Hepatitis C Virus (HCV), or has a history of delta virus
             hepatitis (except for cohort in which delta virus infection is acceptable)

          -  Has hypertension: blood pressure &gt; 170/100 mmHg; well-controlled blood pressure on
             hypertensive medication allowed.

          -  History of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden
             cardiac death

          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe
             cardiovascular disease within 6 months prior to study entry

          -  History of malignancy, except for adequately treated basal cell carcinoma, squamous
             cell skin cancer, superficial bladder tumors, or in situ cervical cancer

          -  Has had major surgery within 1 month of screening

          -  Regular use of alcohol within 6 months prior to screening (ie, more than 14 units of
             alcohol per week).

          -  Use of recreational drugs such as cocaine, phencyclidine (PCP), and methamphetamines,
             within 1 year prior to the screening.

          -  History of allergy to bee sting

          -  Clinically significant history of any alcoholic liver disease, cirrhosis, Wilson's
             disease, hemochromatosis, or alpha-1 antitrypsin deficiency

          -  Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction

          -  Clinically significant history or presence of poorly controlled/uncontrolled systemic
             disease

          -  Presence of any medical or psychiatric condition or social situation that impacts
             compliance or results in additional safety risk

          -  History of coagulopathy/stroke within past 6 months, and/or concurrent anticoagulant
             medication(s)</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Non-randomised trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 2</phase>
    <anticipatedstartdate />
    <actualstartdate>1/12/2015</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>80</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/12/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate>NSW,SA,VIC,WA</recruitmentstate>
    <hospital>Royal Prince Alfred Hospital - Camperdown</hospital>
    <hospital>Concord Repatriation General Hospital, Gastroenterology &amp; Liver Services - Concord</hospital>
    <hospital>St. Vincent's Hospital Sydney - Darlinghurst</hospital>
    <hospital>Westmead Hospital - Westmead</hospital>
    <hospital>Royal Adelaide Hospital - Adelaide</hospital>
    <hospital>Monash Health Clayton Campus - Clayton</hospital>
    <hospital>St. Vincent's Hospital Melbourne - Fitzroy</hospital>
    <hospital>Royal Melbourne Hospital - Parkville</hospital>
    <hospital>Linear Clinical Research Ltd. - Nedlands</hospital>
    <postcode>2050 - Camperdown</postcode>
    <postcode>2139 - Concord</postcode>
    <postcode>2010 - Darlinghurst</postcode>
    <postcode>2145 - Westmead</postcode>
    <postcode>5000 - Adelaide</postcode>
    <postcode>3168 - Clayton</postcode>
    <postcode>3065 - Fitzroy</postcode>
    <postcode>3052 - Parkville</postcode>
    <postcode>6009 - Nedlands</postcode>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Pleven</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Sofia</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Bulgaria</country>
      <state>Varna</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>China</country>
      <state>Hong Kong</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Busan</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Daegu</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Korea, Republic of</country>
      <state>Seoul</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Moldova, Republic of</country>
      <state>Chisinau</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Aukland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Otago-Southland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Yunlin County</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Changhua</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Taiwan</country>
      <state>Kaohsiung</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Bangkok</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Chiang Mai</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Khon Kaen</state>
    </countryoutsideaustralia>
    <countryoutsideaustralia>
      <country>Thailand</country>
      <state>Pathumthani</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arrowhead Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Patients with chronic Hepatitis B Virus (HBV) infection will receive either ARC-520 alone or
      ARC-520 in combination with other treatments such as entecavir (ENT) or tenofovir (TDF)
      and/or pegylated interferon alpha 2a (PEG IFN) therapy, and be evaluated for safety and
      efficacy.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02577029</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>